Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2‐imidazoline receptors in rat liver

@article{Ozaita1997InhibitionOM,
  title={Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2‐imidazoline receptors in rat liver},
  author={A. Ozaita and G. Olmos and M. Assumpci{\'o} Boronat and Jos{\'e} Miguel Lizcano and M. Unzeta and J. Garc{\'i}a-Sevilla},
  journal={British Journal of Pharmacology},
  year={1997},
  volume={121}
}
I2‐Imidazoline sites ([3H]‐idazoxan binding) have been identified on monoamine oxidase (MAO) and proposed to modulate the activity of the enzyme through an allosteric inhibitory mechanism ( Tesson et al., 1995 ). The main aim of this study was to assess the inhibitory effects and nature of the inhibition of imidazol(ine)/guanidine drugs on rat liver MAO‐A and MAO‐B isoforms and to compare their inhibitory potencies with their affinities for the sites labelled by [3H]‐clonidine in the same… Expand
Allosteric modulation of semicarbazide‐sensitive amine oxidase activities in vitro by imidazoline receptor ligands
TLDR
Results reveal an ability of imidazoline ligands to modulate BPAO kinetics allosterically and the derived mechanism may have functional significance with respect to modulation of MAO by I2BS ligands. Expand
High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain.
TLDR
The results indicate that beta-carbolines bind with high affinity to imidazoline I2B receptors, and similarly to I2 ligands (LSL 60101) can block the behavioural and biochemical effects of opiate withdrawal. Expand
Interactions of imidazoline ligands with the active site of purified monoamine oxidase A
TLDR
Flexible docking studies revealed multiple orientations within the large active site, including orientations close to the flavin that would allow oxidation of agmatine. Expand
Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme.
TLDR
Radioligand-binding studies indicated that human liver MAO-B actually existed as two distinct populations that differed in the accessibility of their IBD, suggesting that the IBD and the site involved in enzyme inhibition are distinct. Expand
Labelling of I2B-imidazoline receptors by [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes
TLDR
The results indicate that [3H]2-BFI is a good tool for the identification of I2-imidazoline receptors and suggest further that certain I1-sites and MAO are different proteins. Expand
Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice
TLDR
The loss of I2 binding was found to be regionally dependent and was positively correlated with the relative expression of MAO‐A in specific regions in the wild‐type animals. Expand
Locomotor effects of imidazoline I2‐site‐specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6‐hydroxydopamine lesion of the nigrostriatal pathway
TLDR
It is suggested that I2‐specific ligands have dual effects in the 6‐OHDA‐lesioned rat model of Parkinson's disease; a first effect associated with an increase in activity in the intact hemisphere, and a secondary action which, through the previously documented inhibition of MAO‐A and/orMAO‐B, increases the availability of dopamine produced by L‐DOPA. Expand
On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B.
TLDR
It is confirmed that inactivation of recombinant human MAO-B with tranylcypromine results in the formation of a high affinity I(2) site on the enzyme, measured as an increase in binding of [(3)H]2-BFI. Expand
Pharmacologic and Molecular Discrimination of I2‐Imidazoline Receptor Subtypes a
TLDR
The results indicated that the I2‐IR subtypes differ in their pharmacologic profiles and in the nature of the imidazoline binding site involved in clorgyline and IBI alkylation. Expand
The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat striatum in vivo
TLDR
The I2-imidazoline receptor ligand 2-BFI is also a DA releasing agent in brain, and consequently a DA indirect agonist in vivo. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline‐preferring receptors
1 The binding of [3H]‐idazoxan in the presence of 10−6 m (−)‐adrenaline was used to quantitate I2 imidazoline‐preferring receptors in the rat brain and liver after chronic treatment with variousExpand
Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
TLDR
In rat liver membranes, idazoxan had no effect on MAO activity; it neither inhibited MAO nor prevented the inhibition induced by other imidazolines or MAOIs, suggesting that the ligand recognition site of I2 receptors was distinct from the MAOI target site. Expand
I2-imidazoline binding sites: relationship with different monoamine oxidase domains and identification of histidine residues mediating ligand binding regulation by H+1.
TLDR
Results show that MAO I2BSs are not located within the flavin adenine dinucleotide prosthetic group or the catalytic site of MAOs, and histidine residues appear to be within a MAO domain involved in regulation of [3H]idazoxan binding by H+. Expand
Localization of I2-Imidazoline Binding Sites on Monoamine Oxidases (*)
TLDR
Results show definitely that I2BS is located on both MAO-A and -B, and the fact that I 2BS ligands inhibited MAO activity independently of the interaction with the catalytic region suggests that I1BS might be a previously unknown MAO regulatory site. Expand
Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains.
TLDR
It is demonstrated that I2-imidazoline sites (labeled by [3H]idazoxan) and alpha-2 adrenoceptors are different pharmacological entities with similar characteristics in the human and rat brains. Expand
Pharmacological modulation of immunoreactive imidazoline receptor proteins in rat brain: relationship with non‐adrenoceptor [3H]‐idazoxan binding sites
TLDR
In the rat cerebral cortex the I2‐imidazoline receptor labelled by [3H]‐idazoxan is heterogeneous in nature and the related imidazolin receptor proteins detected by immunoblotting contribute differentially to the modulation of I 2‐sites after drug treatment. Expand
Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down‐regulates non‐adrenoceptor [3H]‐idazoxan binding sites in the rat brain
TLDR
The results disprove a direct interaction between [3H]‐idazoxan and the enzyme MAO and indicate that the two MAO inhibitors irreversibly block the binding of [3h]‐idyzoxan to NAIBS. Expand
Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function
TLDR
Imidazoline sites bind selectively BAG and other guanido ligands thus indicating a distinct structural requirement at its site of binding, and pronounced selectivity for IR over the α2‐adrenoceptors over the IRb subtype which display low affinity for amiloride. Expand
Characterization of the binding of [3H]Ro 41-1049 to the active site of human monoamine oxidase-A.
TLDR
The present results indicate that [3H]Ro 41-1049 is incorporated into a subunit of MAO-A, in the presence of NaBH3CN, and modifies a protein domain that is essential for the enzyme activity. Expand
Imidazoline receptors and their endogenous ligands.
TLDR
The presence of agmatine and its biosynthetic enzyme in synaptosomes and specific neuronal pathways as well as serum suggests that it may be a novel neurotransmitter/hormone. Expand
...
1
2
3
4
5
...